CL2015002701A1 - Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo - Google Patents

Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo

Info

Publication number
CL2015002701A1
CL2015002701A1 CL2015002701A CL2015002701A CL2015002701A1 CL 2015002701 A1 CL2015002701 A1 CL 2015002701A1 CL 2015002701 A CL2015002701 A CL 2015002701A CL 2015002701 A CL2015002701 A CL 2015002701A CL 2015002701 A1 CL2015002701 A1 CL 2015002701A1
Authority
CL
Chile
Prior art keywords
quinuclidin
propan
carbamate
thiazol
fluorophenyl
Prior art date
Application number
CL2015002701A
Other languages
English (en)
Inventor
Craig Siegel
Jin Zhao
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50543351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2015002701A1 publication Critical patent/CL2015002701A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

FORMAS CRISTALINAS DE MALATO DE (2-(2-(4-FLUOROFENIL )TIAZOL-4-IL)PROPAN-2- IL)CARBAMATO DE (S)-QUINUCLIDIN-3-ILO; FORMA CRISTALINA DE (S)-2-HIDROXISUCCINATO DEL MISMO COMPUESTO; FORMA CRISTALINA DE HCL DE DE MISMO COMPUESTO
CL2015002701A 2013-03-15 2015-09-14 Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo CL2015002701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791706P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002701A1 true CL2015002701A1 (es) 2016-03-18

Family

ID=50543351

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002701A CL2015002701A1 (es) 2013-03-15 2015-09-14 Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo

Country Status (34)

Country Link
US (1) US9518049B2 (es)
EP (1) EP2970250B1 (es)
JP (1) JP6438455B2 (es)
KR (1) KR102302064B1 (es)
CN (1) CN105189490A (es)
AR (1) AR095435A1 (es)
AU (1) AU2014240028B2 (es)
BR (1) BR112015022907B1 (es)
CA (1) CA2906691A1 (es)
CL (1) CL2015002701A1 (es)
DK (1) DK2970250T3 (es)
EA (1) EA037527B1 (es)
ES (1) ES2872326T3 (es)
HK (1) HK1214821A1 (es)
HR (1) HRP20210692T1 (es)
HU (1) HUE054349T2 (es)
IL (1) IL241229B (es)
JO (1) JO3713B1 (es)
LT (1) LT2970250T (es)
MA (1) MA38488A1 (es)
MX (1) MX370178B (es)
MY (1) MY181766A (es)
PH (1) PH12015502021A1 (es)
PL (1) PL2970250T3 (es)
PT (1) PT2970250T (es)
RS (1) RS61852B1 (es)
SA (1) SA515361078B1 (es)
SG (1) SG11201507054YA (es)
SI (1) SI2970250T1 (es)
TN (1) TN2015000427A1 (es)
TW (1) TWI713438B (es)
UY (1) UY35439A (es)
WO (1) WO2014152215A1 (es)
ZA (1) ZA201506602B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3079695T3 (pl) * 2013-12-11 2021-09-27 Genzyme Corporation Inhibitory syntazy glukozyloceramidu
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
AU2020218185A1 (en) 2019-02-04 2021-08-26 Genzyme Corporation Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS)
KR20220136887A (ko) * 2020-02-03 2022-10-11 젠자임 코포레이션 리소좀 축적 질환과 연관된 신경계 증상을 치료하기 위한 방법
KR20230043024A (ko) * 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물
EP4188381A1 (en) 2020-07-30 2023-06-07 Genzyme Corporation Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
WO2022215083A1 (en) * 2021-04-05 2022-10-13 Msn Laboratories Private Limited, R&D Center Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP1027069B1 (en) 1997-10-29 2006-07-26 Genzyme Corporation Gene therapy for gaucher disease
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
KR20200034828A (ko) 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
RU2018104472A (ru) * 2011-03-18 2019-02-22 Джензим Корпорейшн Ингибиторы глюкозилцерамид-синтазы

Also Published As

Publication number Publication date
HUE054349T2 (hu) 2021-09-28
BR112015022907A8 (pt) 2019-11-26
JP2016513679A (ja) 2016-05-16
KR102302064B1 (ko) 2021-09-13
MX370178B (es) 2019-12-04
SI2970250T1 (sl) 2021-06-30
MY181766A (en) 2021-01-06
AU2014240028A1 (en) 2015-10-15
IL241229B (en) 2019-12-31
WO2014152215A1 (en) 2014-09-25
TWI713438B (zh) 2020-12-21
PT2970250T (pt) 2021-05-07
ES2872326T3 (es) 2021-11-02
ZA201506602B (en) 2023-04-26
TW201502127A (zh) 2015-01-16
CA2906691A1 (en) 2014-09-25
MA38488A1 (fr) 2017-10-31
AR095435A1 (es) 2015-10-14
PH12015502021A1 (en) 2016-01-11
RS61852B1 (sr) 2021-06-30
TN2015000427A1 (en) 2017-01-03
US20160039805A1 (en) 2016-02-11
EA201591706A1 (ru) 2016-02-29
US9518049B2 (en) 2016-12-13
SA515361078B1 (ar) 2018-06-14
SG11201507054YA (en) 2015-10-29
IL241229A0 (en) 2015-11-30
BR112015022907B1 (pt) 2022-07-12
BR112015022907A2 (pt) 2017-07-18
NZ712659A (en) 2020-11-27
DK2970250T3 (da) 2021-07-12
EP2970250A1 (en) 2016-01-20
KR20150132333A (ko) 2015-11-25
JP6438455B2 (ja) 2018-12-12
CN105189490A (zh) 2015-12-23
PL2970250T3 (pl) 2021-12-06
MX2015012295A (es) 2016-05-16
UY35439A (es) 2014-10-31
HRP20210692T1 (hr) 2021-06-11
EP2970250B1 (en) 2021-04-21
JO3713B1 (ar) 2021-01-31
EA037527B1 (ru) 2021-04-08
AU2014240028B2 (en) 2018-08-02
LT2970250T (lt) 2021-05-10
HK1214821A1 (zh) 2016-08-05

Similar Documents

Publication Publication Date Title
CL2015002701A1 (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo
HK1246296A1 (zh) 多環氨基甲酰基吡啶酮化合物和其用於治療hiv感染的用途
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
HK1223615A1 (zh) 多環氨基甲酰基吡啶酮化合物和其用於治療 感染的用途
PL3409667T3 (pl) Związki amidowe do leczenia zakażeń HIV
DK2958945T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til behandling af cancer
WO2014165128A3 (en) Hepatitis b antiviral agents
DK3474802T3 (da) Medicinsk forbinding
AR095097A1 (es) Compuestos de fenoxietoxi
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2015002358A1 (es) Compuestos bicíclicos.
EP3041514A4 (en) Reducing the risk of major adverse cardiac events
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
ITUA20162283A1 (it) Tonometro indossabile perfezionato
UA37095S (uk) Перев'язувальна пов'язка-бандаж
TWD168624S (zh) 眼鏡（六）
TWD168625S (zh) 眼鏡（七）
UA98069U (xx) N-(3-ТРИФТОРМЕТИЛФЕНІЛ)-2-(2-ОКСО-3,5a,6,11b-ТЕТРАГІДРО-2Н,5Н-ХРОМЕНО[4',3':4,5]ТІОПІРАНО[2,3-d][1,3]ТІАЗОЛ-3-ІЛ)АЦЕТАМІД, ЩО ПРОЯВЛЯЄ АНАБОЛІЧНУ ТА АНДРОГЕННУ ДІЮ
BR302013001836S1 (pt) "configuração aplicada em fone de ouvido"
TH1501001789A (th) อนุพันธ์ของ 1,2,4-ไตรอะซีน สำหรับการบำบัดของโรคติดเชื้อไวรัส